Brief: NeuroNOS Wins FDA Orphan Drug Status for Glioblastoma Therapy
08/09/2025 13:08
Sept 8 (Reuters) - Beyond Air Inc XAIR.O: NEURONOS GRANTED FDA ORPHAN DRUG DESIGNATION FOR GLIOBLASTOMA, THE MOST COMMON AND DEADLIEST PRIMARY MALIGNANT BRAIN CANCER IN ADULTS Source text: ID:nGNX6G0bXW Further company coverage: XAIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyond Air
See all newsBrief: Beyond Air Enters Definitive Agreement To Sell Its NeuroNOS Stake To UNIVO Pharmaceutical Industries In Exchange For Equity And Milestone Payments
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook
Beyond Air Inc expected to post a loss of $10.80 a share - Earnings Preview
NASDAQ RESUMED AT 04:00 AM